In a news release, life sciences company Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB), which develops and commercializes natural antibiotic-free feed products for livestock, companion animal and human applications, announced audited financial results for its fiscal year ended October 31, 2020.
The company's President and CEO Kym Anthony remarked, "By all measures, Avivagen achieved considerable regulatory, customer, corporate and financial success in 2020...We've secured record breaking orders for OxC-beta™ from customers in established markets and received regulatory approval in key markets in Asia and South America. The successes achieved this year position Avivagen very strongly for continued growth worldwide, as we grow recurring order sizes and add new customers and partners in important feed production markets around the globe."
Avivagen discussed several of the highlights of its operational activities in the year noting that it secured approval for OxC-beta Livestock in Malaysia in December 2019 and commented that the Malaysian market's total annual feed production was 4.8 million metric tons in 2019. During the same month, the firm executed an agreement with COFCO Biotech to support the approval process in China. The company stated that COFCO is a leading supplier of agricultural products to the Chinese market and notched sales of more than $17.5 billion in 2018. The firm said it also was granted approval in June 2020 to sell its products in Brazil, which it noted is the world's third largest feed production market.
The firm added that it reached numerous milestones with new and existing customers over the course of the year and noted that it secured its first orders from several countries including Malaysia in December 2019, Mexico in March 2020 and Brazil in August 2020.
In April 2020, Avivagen secured new sales of OxC-beta Livestock in Taiwan and Thailand and then received its largest sales order to date, a three-tonne order from UNAHCO in the Philippines. UNAHCO added another even larger record four-tonne order in October 2020.
In May 2020, a Mexico-based customer placed orders totaling two tonnes and later in September 2020 finalized a record ten-tonne order of OxC-beta from Industrias Melder with delivery schedule to commence in early 2021.
The company reported that for FY/20 it achieved revenues of CA$1,177,857, compared to CA$977,451 in FY/19. The firm stated that it posted a comprehensive loss of CA$4,751,287 in FY/20, versus a loss of CA$4,836,420 in FY/19.
The company advised that in January 2020 it secured two separate private placements totaling CA$3 million. The firm also indicated that its shares began listing on the OTCQB® Venture Market, which is increasing the company's exposure to U.S. investors.
The firm advised that its OxC-beta technology is derived from its β-carotene and other carotenoid discoveries. The company noted that these compounds, which support immune function, are what give many fruits and vegetables their bright colors. Avivagen stated that OxC-beta provides a non-antibiotic means of promoting health and growth. The company listed that its OxC-beta Livestock product is safe and effective and is approved for use in Australia, Brazil, Malaysia, Mexico, New Zealand, the Philippines, Taiwan, Thailand and the U.S.
Read what other experts are saying about:
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
